Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0022 Transporter Info
Gene Name SLC15A2
Transporter Name Peptide transporter 2
Gene ID
6565
UniProt ID
Q16348
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cyclacillin

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A2 (IC50 = 610 microM) [1]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  DT Modulation 2

 Cyclacillin inhibits the transportation of Chephalexin by SLC15A2 (Ki = 36.8 microM) [1]

Affected Drug/Substrate

 Chephalexin Modulation Type Inhibition

  DT Modulation 3

 Cyclacillin inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 39.1 microM) [1]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

  DT Modulation 4

 Cyclacillin inhibits the activity of SLC15A2 [2]

  Amoxicillin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amoxicillin inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 733 microM) [3]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Madin-Darby Canine Kidney (MDCK) cells-PEPT2

  DT Modulation 2

 Amoxicillin inhibits the activity of SLC15A2 [2]

  Cefaclor

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefaclor inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 65 microM) [3]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Madin-Darby Canine Kidney (MDCK) cells-PEPT2

  DT Modulation 2

 Cefaclor inhibits the activity of SLC15A2 [2]

  Cephalexin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephalexin inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 98 microM) [4]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-PEPT2

  DT Modulation 2

 Cephalexin inhibits the activity of SLC15A2 [2]

  Cefadroxil

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefadroxil inhibits the transportation of Glycylsarcosine by SLC15A2 [5]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  DT Modulation 2

 Cefadroxil inhibits the activity of SLC15A2 [2]

  Cefixime

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefixime inhibits the transportation of Glycylsarcosine by SLC15A2 [6]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  DT Modulation 2

 Cefixime inhibits the activity of SLC15A2 [2]

  Losartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Losartan inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 2.4 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  Valsartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valsartan inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 110 microM) [7]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  Ceftibuten

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ceftibuten inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 90 microM) [6]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  Bestatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bestatin inhibits the transporation of melatonin by SLC15A2 (IC50 = 1000 microM) [9]

Affected Drug/Substrate

 Melatonin Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)

  Cefdinir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefdinir inhibits the transportation of Glycylsarcosine by SLC15A2 [6]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  Copper Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Copper Sulfate inhibits the expression of SLC15A2 [10]

  Progesterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Progesterone inhibits the expression of SLC15A2 [11]

  Calcitriol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Calcitriol increases the expression of SLC15A2 [12]

  Testosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Testosterone increases the expression of SLC15A2 [12]

  Zoledronic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zoledronic Acid inhibits the expression of SLC15A2 [13]

  Sunitinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sunitinib inhibits the expression of SLC15A2 [14]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tretinoin increases the expression of SLC15A2 [15]

  Ampicillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ampicillin inhibits the activity of SLC15A2 [2]

  Cefamandole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefamandole inhibits the activity of SLC15A2 [2]

  Cefepime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefepime inhibits the activity of SLC15A2 [2]

  Cefmetazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefmetazole inhibits the activity of SLC15A2 [2]

  Cefotaxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefotaxime inhibits the activity of SLC15A2 [2]

  Cefpodoxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefpodoxime inhibits the activity of SLC15A2 [2]

  Cefuroxime

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefuroxime inhibits the activity of SLC15A2 [2]

  Cephalothin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephalothin inhibits the activity of SLC15A2 [2]

  Cephapirin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephapirin inhibits the activity of SLC15A2 [2]

  Cloxacillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cloxacillin inhibits the activity of SLC15A2 [2]

  Dicloxacillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dicloxacillin inhibits the activity of SLC15A2 [2]

  Oxacillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxacillin inhibits the activity of SLC15A2 [2]

  Valganciclovir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valganciclovir inhibits the activity of SLC15A2 [16]

  Glyburide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Glibenclamide inhibits the activity of SLC15A2 [17]

  Quinapril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinapril inhibits the activity of SLC15A2 [18] , [19]

Drug in Phase 3 Trial

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan inhibits the expression of SLC15A2 [24]

  Benzylpenicillin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzylpenicillin inhibits the activity of SLC15A2 [2]

Drug in Phase 2 Trial

  Genistein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Genistein inhibits the expression of SLC15A2 [21]

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite increases the expression of SLC15A2 [20]

  Dihydrotestosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dihydrotestosterone increases the expression of SLC15A2 [23]

Drug in Preclinical Test

  (+)-JQ1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 (+)-JQ1 increases the expression of SLC15A2 [22]

Discontinued Drug

  MDL-28170

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MDL-28170 inhibits the activity of SLC15A2 [2]

Investigative Drug

  Carnosine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carnosine inhibits the transportation of Glycylsarcosine by SLC15A2 (Ki = 60 microM) [8]

Affected Drug/Substrate

 Glycylsarcosine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-PEPT2

  Laevulinic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Laevulinic acid inhibits the activity of SLC15A2 [2]

Drug Withdrawn

  Cephaloridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephaloridine inhibits the activity of SLC15A2 [2]

Natural Product

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC15A2 [25]
References
1 Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem. 1995 Oct 27;270(43):25672-7.
2 Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51.
3 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
4 Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther. 2004 Dec;311(3):1088-96.
5 Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim Biophys Acta. 1995 May 4;1235(2):461-6.
6 Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2. Biochim Biophys Acta. 1997 Mar 13;1324(2):296-308.
7 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
8 The bioactive dipeptide anserine is transported by human proton-coupled peptide transporters. FEBS J. 2010 Feb;277(3):790-5.
9 Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: An implication of the therapeutic potential. J Pineal Res. 2017 May;62(4).
10 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
11 Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
12 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
13 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
14 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
15 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
16 Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
17 Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. Br J Pharmacol. 1999 Nov;128(6):1159-64.
18 Stoichiometry and kinetics of the high-affinity H+-coupled peptide transporter PepT2. J Biol Chem. 1999 Jan 29;274(5):2773-9.
19 Noncompetitive inhibition of glycylsarcosine transport by quinapril in rabbit renal brush border membrane vesicles: effect on high-affinity peptide transporter. J Pharmacol Exp Ther. 1998 Nov;287(2):684-90.
20 Gene expression changes associated with altered growth and differentiation in benzo[a]pyrene or arsenic exposed normal human epidermal keratinocytes. J Appl Toxicol. 2008 May;28(4):491-508.
21 Dose- and Time-Dependent Transcriptional Response of Ishikawa Cells Exposed to Genistein. Toxicol Sci. 2016 May;151(1):71-87.
22 Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.
23 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
24 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
25 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.